Open-label AZD9291 80 mg/40 mg clinical trials

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

This study looks at a new drug (AZD9291) for people with a certain type of lung cancer (non-small cell lung carcinoma, stages IB-IIIA). It's for patients who have had surgery to remove their tumour, with or without chemotherapy. We want to see if AZD9291 can help prevent the cancer from coming back.